[{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Factors Group of Nutritional Companies Inc.","sponsor":"Isura","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Factors Group of Nutritional Companies Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Factors Group of Nutritional Companies Inc. \/ Isura","highestDevelopmentStatusID":"1","companyTruncated":"Factors Group of Nutritional Companies Inc. \/ Isura"},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ Clarus"},{"orgOrder":0,"company":"Tor Biering-S\u00f8rensen","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tor Biering-S\u00f8rensen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tor Biering-S\u00f8rensen \/ Pharma Nord","highestDevelopmentStatusID":"10","companyTruncated":"Tor Biering-S\u00f8rensen \/ Pharma Nord"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"University of Aarhus | Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aarhus University Hospital \/ University of Aarhus | Pharma Nord","highestDevelopmentStatusID":"8","companyTruncated":"Aarhus University Hospital \/ University of Aarhus | Pharma Nord"},{"orgOrder":0,"company":"BPGbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Inapplicable"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord"},{"orgOrder":0,"company":"Comenius University","sponsor":"Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Comenius University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","highestDevelopmentStatusID":"1","companyTruncated":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o."},{"orgOrder":0,"company":"University of Primorska","sponsor":"Biovis d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Primorska","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Primorska \/ Biovis d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"University of Primorska \/ Biovis d.o.o."},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Nutrients \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nutrients \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Coenzyme Q10

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Tor Biering-Sørensen

                          Country arrow
                          EPSC
                          Not Confirmed

                          Tor Biering-Sørensen

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          November 19, 2024

                          Lead Product(s) : Coenzyme Q10,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Pharma Nord

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Factors Group of Nutritional Companies Inc.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Factors Group of Nutritional Companies Inc.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          November 30, 2023

                          Lead Product(s) : Coenzyme Q10,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Isura

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          September 29, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          July 27, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          University of Primorska

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Primorska

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 09, 2022

                          Lead Product(s) : Coenzyme Q10,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Biovis d.o.o.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Comenius University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Comenius University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          January 05, 2022

                          Lead Product(s) : Coenzyme Q10,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Kaneka Pharma Europe N.V. | Sanatórium of Dr. Guhr, n.o.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Hospital Universitari Vall d'Hebron Research Institute

                          Country arrow
                          EPSC
                          Not Confirmed

                          Hospital Universitari Vall d'Hebron Research Institute

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          November 19, 2021

                          Lead Product(s) : Coenzyme Q10,Selenium

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Pharma Nord

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).

                          Product Name : Ubiquinone

                          Product Type : Enzyme

                          Upfront Cash : $0.4 million

                          September 16, 2021

                          Lead Product(s) : Coenzyme Q10,Caspofungin

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Undisclosed

                          Sponsor : Clarus

                          Deal Size : $40.8 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Aarhus University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Aarhus University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          July 13, 2021

                          Lead Product(s) : Coenzyme Q10,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : University of Aarhus | Pharma Nord

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          February 12, 2021

                          Lead Product(s) : Coenzyme Q10,Vitamin K1,Temozolomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank